IRLAB Therapeutics AB Class A (IRLAB.A) AI Stock Analysis

• Market Cap: €372.42M
• Dividend Yield: N/A
• Average Volume (3M): 24.82K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.27
• Revenue Growth: 1643.36%
• EPS Growth: 50.36%
• Country: SE
• Employees: 31
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.66
• Shares Outstanding: 51,788,630
• 10 Day Avg. Volume: 23,025
• 30 Day Avg. Volume: 24,821
• PEG Ratio: -0.11
• Price to Book (P/B): 7.23
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.58
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

IRLAB Therapeutics has significant financial challenges with operational inefficiencies and high leverage impacting its financial stability. The technical analysis suggests mixed signals with bearish trends, while the negative P/E ratio and lack of dividend yield indicate valuation concerns. These factors collectively result in a low overall stock score.

IRLAB Therapeutics AB Class A Business Overview & Revenue Model

Company Description

IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial for the treatment of Postural dysfunction. Its preclinical stage products include IRL942 and 1009 research programs for the treatment of neurodegenerative disorders and ageing; and IRL757 to treat apathy in neurological diseases. In addition, the company develops P003, a research project that develops drugs for the treatment of newly diagnosed Parkinson's disease. IRLAB Therapeutics AB (publ) was incorporated in 2013 and is based in Gothenburg, Sweden.

How the Company Makes Money

IRLAB Therapeutics AB generates revenue through the development and commercialization of pharmaceutical products targeting neurological conditions. The company primarily earns money by licensing its drug candidates to larger pharmaceutical companies, which may involve upfront payments, milestone payments, and royalties on sales of successfully commercialized products. Additionally, IRLAB may engage in partnerships and collaborations to advance its drug development programs, providing further financial resources and expertise. The company's innovative ISP platform also contributes to its revenue by enabling the identification of promising drug candidates, thereby attracting investment and partnership opportunities.

IRLAB Therapeutics AB Class A Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
94.63M	5.68M	61.14M	207.78M	300.00K
	Gross Profit
94.63M	-122.73M	-111.23M	168.69M	-1.70M
	EBIT
-75.11M	-180.76M	-113.11M	52.58M	-91.46M
	EBITDA
-68.07M	-173.32M	-109.13M	55.37M	-89.46M
	Net Income Common Stockholders
-83.13M	-177.84M	-114.20M	51.78M	-91.85M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
66.92M	111.31M	252.78M	401.90M	277.01M
	Total Assets
136.21M	177.12M	323.56M	472.45M	370.07M
	Total Debt
60.42M	27.57M	3.98M	6.60M	2.93M
	Net Debt
-6.50M	-83.74M	-248.80M	-395.30M	-274.08M
	Total Liabilities
103.58M	61.36M	32.72M	72.97M	22.19M
	Stockholders Equity
32.63M	115.76M	290.83M	399.48M	347.88M
Cash Flow		Free Cash Flow
-65.79M	-165.14M	-145.99M	127.93M	-89.61M
	Operating Cash Flow
-65.59M	-164.85M	-142.61M	128.64M	-89.21M
	Investing Cash Flow
-199.00K	-293.00K	-3.38M	-708.00K	-394.00K
	Financing Cash Flow
21.40M	23.68M	-3.13M	-3.04M	256.09M

IRLAB Therapeutics AB Class A Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.58
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:IRLAB.A, the sentiment is Positive. The current price of 7.58 is above the 20-day moving average (MA) of 7.10, above the 50-day MA of 7.11, and below the 200-day MA of 11.75, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 53.97 is Neutral, neither overbought nor oversold. The STOCH value of 66.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:IRLAB.A.

IRLAB Therapeutics AB Class A Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.14B	3.39	-43.55%	2.83%	16.49%	-0.19%
IRLAB.A	39 Underperform	€372.42M	―	-194.31%	―	1643.36%	50.36%
ONCO	33 Underperform	kr394.22M	―		―	-10.14%	20.91%

IRLAB Therapeutics AB Class A Corporate Events

IRLAB Secures Extended US Patent for Mesdopetam

IRLAB Therapeutics AB has been granted a new patent in the US for the salt form of its drug candidate mesdopetam, which is aimed at treating levodopa-induced dyskinesias in Parkinson’s disease patients. This patent extends the company’s market exclusivity into the 2040s, enhancing the value of mesdopetam and reinforcing IRLAB’s position in the Parkinson’s treatment market.

IRLAB Therapeutics Reports Strong Q1 2025 Progress with Regulatory and Clinical Advances

IRLAB Therapeutics AB reported significant progress in the first quarter of 2025, with positive regulatory feedback from the EMA aligning with the FDA on Phase III for Mesdopetam and promising Phase I results for IRL757. The company also announced a fully funded IRL757 study in Parkinson’s disease and a Phase IIB study with Pirepemat showing a meaningful reduction in fall frequency, strengthening its market position and operational outlook.